Separate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells
Huijie Xiao(Union Hospital), Feng Wang(Sun Yat-sen University)
Cited by 29
Related Papers
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
|Nature Medicine|2024|162
A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio
|BMC Cancer|2015|160
Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer
|Journal of Experimental & Clinical Cancer Research|2019|70
STAT3 regulates hypoxia-induced epithelial mesenchymal transition in oesophageal squamous cell cancer
|Oncology Reports|2016|58
A phase I study of toripalimab, an anti‐PD‐1 antibody, in patients with refractory malignant solid tumors
|Cancer Communications|2020|54